Literature DB >> 20921429

Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.

Michael W Brands1, Amy K L Banes-Berceli, Edward W Inscho, Hind Al-Azawi, Ashlyn J Allen, Hicham Labazi.   

Abstract

Chronic angiotensin II (Ang II) infusion stimulates interleukin (IL) 6 release, and we and others have shown that preventing the increase in IL-6 significantly attenuates Ang II hypertension. This study measured renal blood flow (RBF) chronically, using Transonic flow probes in wild-type (WT) and IL-6 knockout (KO) mice, to determine the role of RBF regulation in that response. Ang II infusion at 200, 800, and 3600 ng/kg per minute caused a dose-dependent decrease in RBF in WT mice, and the response at 800 ng/kg per minute was compared between WT and IL-6 KO mice. Ang II infusion increased plasma IL-6 concentration in WT mice and increased mean arterial pressure (19 h/d with telemetry) from 113±4 to 149±4 mm Hg (Δ36 mm Hg) over the 7-day infusion period, and that effect was blocked in IL-6 KO mice (119±7 to 126±7 mm Hg). RBF decreased to an average of 61±8% of control over the 7-day period (control: 0.86±0.02 mL/min) in the WT mice; however, the average decrease to 72±6% of control (control: 0.88±0.02 mL/min) in the KO mice was not significantly different. There also was no difference in afferent arteriolar constriction by Ang II in blood-perfused juxtamedullary nephrons in WT versus KO mice. Phosphorylation of janus kinase 2 and signal transducer and activator of transcription 3 in renal cortex homogenates increased significantly in Ang II-infused WT mice, and that effect was prevented completely in Ang II-infused IL-6 KO mice. These data suggest that IL-6-dependent activation of the renal janus kinase 2/signal transducer and activator of transcription 3 pathway plays a role in Ang II hypertension but not by mediating the effect of Ang II to decrease total RBF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20921429      PMCID: PMC3500610          DOI: 10.1161/HYPERTENSIONAHA.110.158071

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  37 in total

1.  Role of extracellular superoxide dismutase in the mouse angiotensin slow pressor response.

Authors:  William J Welch; Tinatin Chabrashvili; Glenn Solis; Yifan Chen; Pritmohinder S Gill; Shakil Aslam; Xiaoyan Wang; Hong Ji; Kathryn Sandberg; Pedro Jose; Christopher S Wilcox
Journal:  Hypertension       Date:  2006-10-02       Impact factor: 10.190

2.  Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.

Authors:  James M Luther; James V Gainer; Laine J Murphey; Chang Yu; Douglas E Vaughan; Jason D Morrow; Nancy J Brown
Journal:  Hypertension       Date:  2006-10-16       Impact factor: 10.190

3.  Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells.

Authors:  F Amiri; V J Venema; X Wang; H Ju; R C Venema; M B Marrero
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

4.  Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability.

Authors:  B Schieffer; E Schieffer; D Hilfiker-Kleiner; A Hilfiker; P T Kovanen; M Kaartinen; J Nussberger; W Harringer; H Drexler
Journal:  Circulation       Date:  2000-03-28       Impact factor: 29.690

5.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men.

Authors:  S E Humphries; L A Luong; M S Ogg; E Hawe; G J Miller
Journal:  Eur Heart J       Date:  2001-12       Impact factor: 29.983

6.  P2 receptor-mediated afferent arteriolar vasoconstriction during calcium blockade.

Authors:  Edward W Inscho; Anthony K Cook
Journal:  Am J Physiol Renal Physiol       Date:  2002-02

Review 7.  Inflammation in hypertension.

Authors:  Carmine Savoia; Ernesto L Schiffrin
Journal:  Curr Opin Nephrol Hypertens       Date:  2006-03       Impact factor: 2.894

8.  Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation.

Authors:  Amy K L Banes-Berceli; Pimonrat Ketsawatsomkron; Safia Ogbi; Bela Patel; David M Pollock; Mario B Marrero
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-05-25       Impact factor: 4.733

9.  Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.

Authors:  Tomasz J Guzik; Nyssa E Hoch; Kathryn A Brown; Louise A McCann; Ayaz Rahman; Sergey Dikalov; Jorg Goronzy; Cornelia Weyand; David G Harrison
Journal:  J Exp Med       Date:  2007-09-17       Impact factor: 14.307

10.  Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo.

Authors:  Barbara Coles; Ceri A Fielding; Stefan Rose-John; Jürgen Scheller; Simon A Jones; Valerie B O'Donnell
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

View more
  83 in total

1.  Does interleukin 6 contribute to renal hemodynamic changes during angiotensin II-dependent hypertension?

Authors:  Michael J Ryan
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage.

Authors:  Weiru Zhang; Wei Wang; Hong Yu; Yujin Zhang; Yingbo Dai; Chen Ning; Lijian Tao; Hong Sun; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  Hypertension       Date:  2011-11-07       Impact factor: 10.190

Review 3.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

4.  Angiotensin II utilizes Janus kinase 2 in hypertension, but not in the physiological control of blood pressure, during low-salt intake.

Authors:  Amy K L Banes-Berceli; Hind Al-Azawi; Daniel Proctor; Harvey Qu; Dominic Femminineo; Crystal Hill-Pyror; R Clinton Webb; Michael W Brands
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-03       Impact factor: 3.619

Review 5.  The immune system in hypertension.

Authors:  Daniel W Trott; David G Harrison
Journal:  Adv Physiol Educ       Date:  2014-03       Impact factor: 2.288

Review 6.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

7.  ROCK/NF-κB axis-dependent augmentation of angiotensinogen by angiotensin II in primary-cultured preglomerular vascular smooth muscle cells.

Authors:  Kayoko Miyata; Ryousuke Satou; Weijian Shao; Minolfa C Prieto; Maki Urushihara; Hiroyuki Kobori; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-15

Review 8.  Neuroimmune communication in hypertension and obesity: a new therapeutic angle?

Authors:  Annette D de Kloet; Eric G Krause; Peng D Shi; Jasenka Zubcevic; Mohan K Raizada; Colin Sumners
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

9.  Role of proopiomelanocortin neuron Stat3 in regulating arterial pressure and mediating the chronic effects of leptin.

Authors:  John H Dubinion; Jussara M do Carmo; Ahmad Adi; Shereen Hamza; Alexandre A da Silva; John E Hall
Journal:  Hypertension       Date:  2013-03-25       Impact factor: 10.190

10.  Synapses, signals, CDs, and cytokines: interactions of the autonomic nervous system and immunity in hypertension.

Authors:  Meena S Madhur; David G Harrison
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.